- Home
- NDRA vs CNSP Comparison
NDRA vs CNSP Comparison
Compare NDRA & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDRA | CNSP |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 8.5M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NDRA | CNSP |
|---|---|---|
| Price | $4.54 | $4.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.3K | ★ 16.9K |
| Earning Date | 11-20-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.32 | 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.96 | $1.90 |
| 52 Week High | $6.95 | $10.54 |
Technical Indicators
Market Signals| Indicator | NDRA | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 34.89 |
| Support Level | $4.28 | $2.01 |
| Resistance Level | $5.24 | $4.00 |
| Average True Range (ATR) | 0.36 | 0.64 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 59.41 | 12.57 |
Price Performance
Historical ComparisonAbout NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.